ALLO
Allogene Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$690.31M
P/E Ratio
—
EPS
$-0.77
Beta
0.46
52W High
$4.46
52W Low
$0.98
50-Day MA
$2.31
200-Day MA
$1.68
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-131.96M |
| EBITDA | $-175.70M |
| Operating Margin | 0.00% |
| Return on Equity | -52.30% |
| Return on Assets | -26.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.14 |
| Price-to-Book | 2.48 |
| Price-to-Sales (TTM) | 7784.36 |
| EV/Revenue | 3859.62 |
| EV/EBITDA | -1.04 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $345.15M |
| Float | $269.64M |
| % Insiders | 11.05% |
| % Institutions | 52.91% |
Historical Volatility
HV 10-Day
61.15%
HV 20-Day
58.03%
HV 30-Day
109.27%
HV 60-Day
104.64%
HV Rank
71.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($8.35 target)
3
Strong Buy10
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026